%0 Journal Article
%T Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy
%A Andreas Kuznik
%A Chieh-I Chen
%A Clare Proudfoot
%A Donna McMorrow
%A Machaon M. K. Bonafede
%A Shraddha Shinde
%J Archive of "American Health & Drug Benefits".
%D 2018
%X Targeted disease-modifying antirheumatic drug (DMARD) options for rheumatoid arthritis (RA) include tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) or alternative mechanisms of action (MOAs), such as a T-cell co-stimulation modulator (abatacept), Janus kinase inhibitor (tofacitinib), or interleukin-6 inhibitor (tocilizumab)
%K alternative mechanisms of action
%K cost
%K persistence
%K rheumatoid arthritis
%K switching treatment
%K synthetic DMARD
%K treatment cycling
%K treatment persistence
%K tumor necrosis factor inhibitors
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207310/